KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.5840 (−94.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Karyopharm Therapeutics Inc. grew revenue 6.8% to $146.62M over the twelve months to Jun 30, 2026. Free cash flow was -$75.37M.
Revenue
$146.62M
+6.8% vs. a year earlier
Operating income
-$82.35M
TTM Q2 2026
Free cash flow
-$75.37M
FY2025
EPS, diluted
-$17.93
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.01K
- P/E ratio
- –
- Price to sales
- 0.00
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -752745.46%
Fundamentals
- Revenue
- $146.62M
- Net income
- -$224.74M
- EPS, diluted
- -$17.93
- Free cash flow
- -$75.37M
- Book value per share
- -$11409.50
- Diluted shares
- 0M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$146.62M+6.8% YoY
Operating income
-$82.35M
Net income
-$224.74M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months